glaxosmithkline organizational structure

1. GlaxoSmithkline

2. HISTORY
 GlaxoSmithKline started operations on 1 January 2001 following the merger of
GlaxoWellcome group and SmithKline Beecham group, but their combined histories
go back much further than that.
 Beginning with
1715: Plough Court Pharmacy was established
1830: John K Smith opened his first drugstore
1842: Beecham’s Pills brand was launched
2000: Planned merger of Glaxo Wellcome and SmithKline Beecham was announced

3. Mission : Do more, Feel Better, Live Longer.
 The business is focused around the delivery of three strategic priorities which aim
to increase growth, reduce risk and improve the company’s long-term financial
performance.
 These priorities are:
• Grow a diversified global business,
• Deliver more products of value,
• Simplify the operating model.

4. What GSK does?
 GSK is a science-led global healthcare company. It researches and develops a
broad range of innovative products in three primary areas viz., Pharmaceuticals,
Vaccines and Consumer Healthcare.
 GSK has a significant global presence with commercial operations in more
than 150 countries, a network of 84 manufacturing sites in 36 countries and large
R&D centres in the UK, USA, Spain, Belgium and China.

5. Pharmaceuticals
 GSK’s Pharmaceuticals business develops and makes medicines to treat a broad
range of acute and chronic diseases. It’s portfolio is made up of both patent-
protected and off patent medicines. Such as, products for major disease areas like
asthma, cancer, infections, mental health, diabetes and digestive conditions.
£15.5bn turnover 67% of Group

6. Vaccines
GSK’s Vaccines business is one of the largest in the world, producing paediatric and
adult vaccines against a range of infectious diseases. In 2014, it distributed more
than 800 million doses to 170 countries, of which over 80% were supplied to
developing countries.
£3.2bn turnover 14% of Group

7. Consumer Healthcare
GSK’s Consumer Healthcare business develops and markets a range of products in
the areas of: Pain Relief, Respiratory, Oral Health, Nutrition/Gastro Intestinal and Skin
Health. These include a number of well-known global brands such
as Sensodyne, Parodontax, Poligrip, Voltaren, Aquafresh toothpaste, Horlicks,
Panadol, Breathe right nasal strips, Otrivin and Theraflu.
£4.3bn turnover 19% of Group

8. Governance
Sir Philip Hampton,
Chairman

9. Corporate Executive Team (CET)
Sir Andrew Witty: GSK CEO
& member of the Board
&Corporate Executive
Team
Roger Connor: President, Global
Manufacturing & Supply
Simon Dingemans: Chief Financial
Officer
Nick Hirons: Senior Vice President,
Global Ethics and Compliance
Abbas Hussain: President, Global
Pharmaceuticals
David Redfern:
Chief Strategy Officer
Dr, Moncef Slaoui: Chairman, Global
Vaccines
Claire Thomas:
Senior Vice President, Human
Resources
Phil Thomson:
Senior Vice President,
Communications and Government
Affairs
Don Troy:
Senior Vice President & General
Counsel
Patrick Vallance: President,
Pharmaceuticals R&D
Emma Walmsley:
CEO, GSK Consumer Healthcare

10. Board committees
Audit And Risk Committee
Remuneration Committee
Nominations Committee
Finance Committee
Corporate Social Responsibility Committee
Corporate Administration and Transactions Committee

11. Audit and risk Committee
Members:
Stacey Cartwright
Lynn Elsenhans
Sir Deryck Maughan
Dr. Daniel Podolsky
Secretary:
Victoria Whyte
In attendance:
Chairman
CEO, CFO,General Counsel
Chairman, Global Vaccines Head of Audit
& Assurance
SVP, Global Ethics & Compliance
Chief Medical Officer, Representative of
external auditors, Financial Controller
Frequency of meetings:
Not less than four times a year
The Audit & Risk Committee reviews:
 The integrity of financial and internal reporting
process
 The integrity of financial statements
 The external and internal audit processes
 The system of internal controls and the
identification and management of risks
 The committee also proposes to shareholders
the appointment, re-appointment and removal
of external auditors and is directly responsible
for their remuneration and oversight of their
work.
Chair: Judy Lewent

12. Remuneration Committee
Members:
Dr Stephanie Burns
Judy Lewent
Sir Deryck Maughan
Hans Wijers
Secretary:
Victoria Whyte
In attendance:
CEO, Head of Human
Resources, Head of Reward,
Committee adviser - Deloitte
LLP, Any Non-Executive
Director shall be entitled to
attend the committee
meetings.
Frequency of meetings:
Four times a year and otherwise as necessary.
 The Committee consists of Independent Non-
Executive Directors and the Chairman
 The Chairman and the CEO are responsible for
evaluating and making recommendations to the Board
on the remuneration of Non-Executive Directors
within the terms of the approved Remuneration Policy
Chairman: Urs Rohner

13. Nominations Committee
Members:
Professor Sir Roy Anderson
Sir Deryck Maughan
Judy Lewent
Lynn Elsenhans
Secretary:
Victoria Whyte
In attendance:
CEO, Head of Human Resources,
External Advisers - as appropriate
Frequency of meetings:
 The committee meets at least
twice a year to consider
succession planning, with other
meetings held as required.
The Nominations Committee reviews the
structure, size and composition of the Board and
the appointment of members to the Board and
the CET. The committee also monitors the
planning of succession to the Board and senior
management. It is also responsible for
considering and, if appropriate, authorising
conflicts of interest. The committee consists of
Independent Non-Executive Directors and the
Chairman.
Chairman:
Sir Philip Hampton

14. Finance Committee
Members:
All directors
Secretary:
Victoria Whyte
Frequency of meetings:
Held as necessary.
The Finance Committee reviews and approves the
following on behalf of our Board:
 The annual report
 Form 20-F (for financial reporting in the US)
 The convening of the annual general meeting
 Preliminary and quarterly statements of trading
results, dividends and major licensing and capital
transactions
Each director is a member of the committee and a
meeting can comprise just three members but must
include the company chairman, or the chairman of the
audit & risk committee, and the CEO or CFO

15. CSR Committee
Members:
Dr Stephanie Burns
Lynn Elsenhans
Dr Daniel Podolsky
Hans Wijers
Secretary:
Victoria Whyte
In attendance: CEO, Head of Communications and
Government Affairs, Head of Human Resources,
General Counsel, Head of Corporate
Responsibility and Reporting, Global
Pharmaceuticals (President), Pharmaceutical
R&D(President), Consumer Healthcare(President),
Global Manufacturing & Supply(President),
Independent External Corporate Responsibility
Adviser
Other executives are invited to attend the
Committee as necessary
Frequency of meetings:
Four times a year or more frequently as
necessary.
The Corporate Responsibility Committee
provides a Board-level forum for the review
of external issues that could potentially
impact upon our business and reputation.
The Committee is also responsible for
overseeing our worldwide charitable
donations and community support. The
Committee consists of Independent Non-
Executive Directors and the Chairman.
Chairman:
Lynn Elsenhans

16. Corporate Administration and Transactions
Committee
 Members:
Directors, CET members and the Company
Secretary
 Frequency of meetings:
Held as necessary.
 The Corporate Administration and
Transactions Committee reviews and
approves matters in connection with the
administration of the business, and of
certain corporate transactions. The
committee consists of the directors,
Corporate Executive Team members and
the Company Secretary.

17. Some Facts and Figures
 As of 2013 GSK had offices in over 115
countries and employed over 90,000
people, 12,500 in R&D.
 The company's single largest market is the
United States. Its US headquarters are
in The Navy Yard, Philadelphia,
and Research Triangle Park, North
Carolina; its consumer-products division is
in Moon Township, Pennsylvania.
 Total No. of Employees (2015): 96,575
 Net Income(2014): £2.831 billion
 As of 6 May 2015 it had a Market
Capitalization of £73 billion, the fourth-
largest of any company listed on the
London Stock Exchange.

18. Key achievements
We are the 1st pharmaceutical
company to sign up to the
AllTrials campaign for research
transparency.
We invested £3.1 billion in 2014
in our search to develop new
medicines, vaccines and
consumer products.
Four new products approved
in 2014
We have around 40 new
molecular entities in
phase II/III development.
We have 84 manufacturing
sites in 36 countries making
our medicines, vaccines and
consumer healthcare
products.
4 billion albendazole tablets
donated to eliminate two
neglected tropical diseases
since 1998.
More than 13,000 people work in R&D
in our search for new medicines,
vaccines and consumer healthcare
products.
In 2014, we distributed more
than 800 million doses of
vaccines around the world.
We employ around 98,000
people in over 100 countries,
with more than a third of these in
emerging markets.
In March 2015 we acquired Novartis’s
vaccines business (excluding influenza
vaccines) and combined our Consumer
Healthcare businesses to create a new
company.

19. References:
 https://www.gsk.com/
 https://en.wikipedia.org/wiki/GlaxoSmithKline
 www.google.com

20. Thankyou